WHAT IS OVA1TM OVARIAN TUMOR TRIAGE TEST?
A qualitative immunoassay test that produces a 0 to 10 score based on changes identified in 5 biomarker proteins (transthyretin, apolipoprotein A1, β2-microglobulin, transferrin, and CA-125 II cancer antigen) that increase when ovarian malignancy is present. Test results use the OvaCalcTM, a proprietary method to combine the results of the serum levels of the 5 proteins into a single score indicating risk of malignancy. Sensitivity is highest (96%) in women who are postmenopausal and lowest (89%) in women who are premenopausal. In all women, sensitivity is 92%. The sensitivity of 89% for OVA1 is higher than CA-125 (60%), and specificity is low (43%). This could result in referrals of benign conditions to gynecologic oncology surgeons; however, it would not cause added risk to the client. A major benefit of using OVA1 over CA-125 is that the increased sensitivity identifies more than 70% of malignancies not identified using the American College of Obstetricians and Gynecologists guidelines for referral of patients with a pelvic mass.